TOP 100 MEDICAL SITES
| |||
|
| |||
| |||
|
| |||
| Testimony Excluded in Bausch & Lomb Case A U.S. judge has excluded the testimony of an expert witness in a series of personal-injury lawsuits against Bausch & Lomb over a contact-lens solution recalled in 2006 because of links to a serious fungal eye infection. sec.online.wsj.com |
Report: Tysabri Concerns Will Weigh on Biogen Concern about the risk of brain infection in multiple-sclerosis patients will continue to hurt Biogen stock, Barclays says. online.barrons.com |
Novartis Highlights New Drug Tasigna Novartis said its leukemia drug Tasigna worked better than the company's older product Gleevec in a clinical trial, underpinning expectations that Novartis is positioning Tasigna to replace Gleevec when the latter drug loses patent protection in 2015. online.wsj.com |
Limited Effect Seen in Abortion Clause Restrictions on abortion coverage approved in the House version of the health-care bill likely will affect the affordability of the procedure for only a small minority of women. online.wsj.com |
Starting a Position in Human Genome Sciences Trader Mark submits:As complacency washes over me, I am beginning a 2.1% stake in Human Genome Sciences (HGSI) as the stock crosses the $30 threshold; this stock was highlighted late yesterday. This is a buy completely for technical reasons, as the chart is almost a direct mirror of the S&P 500... a very long base, from which the assumption is a breakout shall ensue. Stop loss will be placed slightly below the blue line (20 day moving average) although $27 has been a good floor during the base building of November & December. If the stock starts breaking out i.e. $31+, I'll add more. EDIT 12:35 PM - I added more exposure in mid $30's, as the computers have picked up what I have flagged... the stock looks strong. Will add more on a break over $31.Complete Story » seekingalpha.com |